Introduction {#H1-1-ZOI200134}
============

More than 1 million Americans live with HIV and an additional 1.2 million individuals have indications that make them eligible for medications to reduce risk for acquiring HIV infection.^[@zoi200134r1],[@zoi200134r2],[@zoi200134r3]^ Despite effective antiretroviral (ARV) drugs for treatment and prevention, approximately 38 000 persons are newly infected with HIV annually, a number remaining essentially unchanged since 2012.^[@zoi200134r1],[@zoi200134r2],[@zoi200134r3]^ The 2019 federal Ending the HIV Epidemic initiative seeks a 75% reduction in new HIV infections by 2025 and a 90% reduction by 2030.^[@zoi200134r4]^ The program's success requires a rapid and substantial increase in the use of ARVs. Suppressive ARV therapy (ART) for persons with HIV is associated with undetectable virus levels, thus preventing transmission to others, and preexposure prophylaxis (PrEP) for persons at risk for HIV may be associated with a more than 90% lower risk of infection.^[@zoi200134r5]^

Antiretroviral therapy and PrEP cost tens of thousands of dollars annually.^[@zoi200134r6],[@zoi200134r7]^ Consequently, the financial burden to patients is a concerning barrier to expanding ARV use.^[@zoi200134r6],[@zoi200134r7],[@zoi200134r8],[@zoi200134r9],[@zoi200134r10],[@zoi200134r11]^ Furthermore, ARV prices continue to increase steadily,^[@zoi200134r7],[@zoi200134r12],[@zoi200134r13],[@zoi200134r14]^ with a 34% price increase between 2012 and 2018.^[@zoi200134r7]^ High ARV prices also affect taxpayers. Historically, many people with HIV relied on Medicaid (federally or state-subsidized health coverage for lower-income persons) owing to disabilities from HIV prior to the availability of effective ART.^[@zoi200134r15]^ However, Medicare, which covers persons aged 65 years or older or younger persons with permanent disabilities, has played an increasingly important role in federal funding for HIV care. In 2006, the Patient Protection and Affordable Care Act began automatically enrolling Medicaid beneficiaries with Social Security Disability Insurance into dual coverage with Medicare after 2 years.^[@zoi200134r15]^ By 2014, approximately 1 in 4 persons with HIV who received care were insured in part through Medicare.^[@zoi200134r15]^ Most Medicare beneficiaries with HIV qualify for coverage on disability alone (79% in 2014). However, an increasing number of individuals with HIV enter Medicare by reaching 65 years or older (13% in 2014) because ART enables people with HIV to live longer and age in a healthy manner.^[@zoi200134r15]^

In this study, we examined cost-sharing for ART and PrEP under Medicare Part D, the drug benefit that covers 70% of Medicare beneficiaries.^[@zoi200134r16]^ Medicare beneficiaries with HIV are even more likely to have Part D coverage because dually eligible individuals (Medicare and Medicaid) automatically receive Part D benefits.^[@zoi200134r15],[@zoi200134r16]^ By federal mandate, Part D must cover all ARVs as 1 of 6 specially protected drug classes.^[@zoi200134r16]^ However, as designed, Part D also imposes cost-sharing among patients, insurers, manufacturers, and Medicare that varies throughout the year.^[@zoi200134r16]^ Studies for other conditions, such as cancer and rheumatoid arthritis, have shown that Part D enrollees can face substantial out-of-pocket costs for expensive drugs even when these drugs are covered by Part D.^[@zoi200134r17],[@zoi200134r18]^ Patients must pay an initial deductible, followed by a coverage phase (insurance plans pay most of the cost, but patient cost-sharing is required), then a coverage gap (costs are shared between the patient, the insurance plan, and the manufacturer), and finally a catastrophic coverage phase (Medicare pays 80% of the cost, with the remainder shared by the insurance plan and the patient).^[@zoi200134r16]^ For individuals with qualifying low income and assets and for dually eligible enrollees, Medicare provides a full or partial low-income subsidy (LIS) that covers all or part of the out-of-pocket costs.^[@zoi200134r16]^ In 2014, 77% of Medicare beneficiaries with HIV received an LIS.^[@zoi200134r15]^

This complicated Part D cost-sharing structure obscures who carries the cost burden for high-priced ART and PrEP. However, the way in which Part D distributes the high cost of ART and PrEP to its enrollees and to taxpayers may affect how much patients and society pay to prevent or control HIV. We analyzed how cost is shared between patients, insurance plans, manufacturers, and Medicare for 1 year of ART or PrEP, and how this cost-sharing would differ for patients qualifying for full taxpayer subsidies.

Methods {#H1-2-ZOI200134}
=======

We analyzed the first quarter 2019 Medicare formulary and pricing files for 3326 Part D insurance plans nationwide.^[@zoi200134r19]^ Files contain drug benefit data for each insurance plan (formulary coverage, 30-day list prices for drugs, and copayments and coinsurance requirements) and not patient claims. We averaged prices and the out-of-pocket cost requirements for 18 first-line ART regimens based on US Department of Health and Human Services recommendations and 2 US Food and Drug Administration--approved PrEP regimens.^[@zoi200134r20]^ This study was approved by the University of Hawaii Institutional Review Board and the Massachusetts General Hospital Partners Human Research Committee. The databases contain insurance plans' drug benefit design information (no patient data), and therefore this study did not require informed consent.

For each regimen, we projected the proportion of annual treatment cost paid by the patient, insurance plan, manufacturer, and Medicare under a standard 2019 Part D insurance plan consisting of the following 4 phases^[@zoi200134r16]^: (1) the patient deductible phase, fixed at \$415; (2) the covered phase, in which patients pay part of the drug price (set as mean cost-sharing requirements by Part D plans nationwide), with the remaining cost paid by the insurance plan; (3) the "donut hole" or coverage gap: once total drug costs reach \$3820, brand-name drug costs are shared by the patient (25%), manufacturer (70%), and insurance plan (5%), while generic drug costs are shared by the patient (37%) and manufacturer (63%); and (4) catastrophic coverage: after out-of-pocket costs (including manufacturers' discounts for brand-name drugs during the gap) total \$5100, costs are borne by the patient (5%), insurance plan (15%), and Medicare (80%) until the end of the year. Part D bases all coinsurance cost-sharing on a drug's full list price, which excludes rebates and discounts to plans.^[@zoi200134r21]^ For each monthly prescription, we prorated the proportion of drug price falling into each Part D phase and calculated cost-sharing accordingly. We also considered a full LIS scenario, in which Medicare absorbs virtually all of a patient's out-of-pocket costs for ART and PrEP throughout the year.^[@zoi200134r22]^

Analyses were based on patients using the specific ART or PrEP regimen and no other drugs. We used simple descriptive statistics to present mean monthly prices and out-of-pocket cost requirements across all plans, rounded to the nearest \$10.

Results {#H1-3-ZOI200134}
=======

In 2019, mean (SD) monthly prices of ART ranged from \$2000 (\$140) to \$3900 (\$110), with a median monthly price of \$2980, and the mean (SD) monthly price of PrEP was \$1710 (\$60) ([Table 1](#zoi200134t1){ref-type="table"}). During the coverage phase, insurance plans almost universally structured patient cost-sharing as a coinsurance (ie, a percentage of a drug's list price \[range, 28.1%-30.8%\] rather than charging a fixed dollar copayment). This cost-sharing structure parallels the coinsurance required in the coverage gap (25%) and catastrophic (5%) phases. For ART, the monthly out-of-pocket costs after the deductible were high in the coverage phase (mean \[SD\]: range, \$550 \[\$160\]-\$1160 \[\$210\]) and coverage gap phase (range, \$530-\$970) and remained considerable even after reaching catastrophic coverage (mean: range, \$100-\$195). For all ART regimens, patients were projected to reach catastrophic coverage between February and May. For PrEP, monthly out-of-pocket costs were high in the coverage phase (mean \[SD\], \$480 \[\$70\]) and gap phase (mean, \$430) before reaching the catastrophic phase (mean, \$90) in May.

###### Antiretroviral Therapy and Preexposure Prophylaxis Prices and Patient Out-of-Pocket Cost During Each Phase of a 2019 Medicare Part D Plan[^a^](#zoi200134t1n1){ref-type="table-fn"}

  Drug regimen                                                       Cost per 30 d, mean (SD), \$   Patient out-of-pocket cost per 30 d, mean (SD), \$   Coinsurance, %   Months in each Part D phase[^b^](#zoi200134t1n2){ref-type="table-fn"}                              
  ------------------------------------------------------------------ ------------------------------ ---------------------------------------------------- ---------------- ----------------------------------------------------------------------- ------ --------- --------- ----------
  Antiretroviral therapy[^d^](#zoi200134t1n4){ref-type="table-fn"}                                                                                                                                                                                                           
  BIC, TAF, and FTC                                                  3090 (90)                      910 (160)                                            770              155                                                                     29.7   Jan-Feb   Feb-Mar   Mar-Dec
  DTG, ABC, and 3TC                                                  2950 (100)                     870 (150)                                            740              148                                                                     29.7   Jan-Feb   Feb-Mar   Mar-Dec
  DTG+TAF and FTC                                                    3490 (120)                     980 (140)                                            870              175                                                                     28.1   Jan-Feb   Feb-Mar   Mar-Dec
  RAL+TAF and FTC                                                    3240 (100)                     900 (140)                                            810              162                                                                     28.1   Jan-Feb   Feb-Mar   Mar-Dec
  EVG, C, TDF, and FTC                                               3160 (100)                     930 (160)                                            790              158                                                                     29.7   Jan-Feb   Feb-Mar   Mar-Dec
  EVG, C, TAF, and FTC                                               3010 (100)                     840 (120)                                            750              151                                                                     28.1   Jan-Feb   Feb-Mar   Mar-Dec
  RAL+ABC and 3TC                                                    2120 (350)                     560 (160)                                            600              106                                                                     29.0   Jan-Feb   Feb-May   May-Dec
  DRV, C, TAF, and FTC                                               3900 (110)                     1160 (210)                                           970              195                                                                     29.8   Jan       Jan-Feb   Feb-Dec
  DRV, R+TAF, and FTC                                                3690 (120)                     1060 (170)                                           920              185                                                                     28.9   Jan-Feb   Feb-Mar   Mar-Dec
  ATV, C+TAF, and FTC                                                3350 (110)                     960 (160)                                            840              168                                                                     28.9   Jan-Feb   Feb-Mar   Mar-Decr
  DRV, R+ABC, and 3TC                                                2560 (370)                     720 (190)                                            710              128                                                                     29.8   Jan-Feb   Feb-Apr   Apr-Dec
  DOR, TDF, and 3TC                                                  2200 (60)                      650 (120)                                            550              110                                                                     29.8   Jan-Feb   Mar-Apr   Apr-Dec
  EFV, TDF, and FTC                                                  2790 (90)                      780 (110)                                            700              140                                                                     28.1   Jan-Feb   Feb-Mar   Mar-Dec
  RPV, TAF, and FTC                                                  2740 (90)                      770 (110)                                            690              137                                                                     28.1   Jan-Feb   Feb-Mar   Mar-Dec
  RPV, TDF, and FTC                                                  2740 (90)                      810 (140)                                            680              137                                                                     29.8   Jan-Feb   Feb-Mar   Mar-Dec
  DTG+3TC                                                            2000 (140)                     550 (100)                                            530              100                                                                     30.0   Jan-Feb   Feb-May   May-Dec
  DRV and R+RAL                                                      3500 (110)                     1010 (170)                                           880              175                                                                     28.9   Jan-Feb   Feb-Mar   Mar-Dec
  DRV and R+3TC                                                      2190 (150)                     640 (130)                                            580              110                                                                     30.8   Jan-Feb   Feb-Apr   Apr-Dec
  Median price                                                       2980                           860                                                  750              149                                                                     29.4   Jan-Feb   Feb-Mar   Mar-Dec
  Preexposure prophylaxis                                                                                                                                                                                                                                                    
  TDF and FTC                                                        1710 (60)                      480 (70)                                             430              90                                                                      28.1   Jan-Mar   Mar-May   May-Dec
  TAF and FTC                                                        1710 (60)                      480 (70)                                             430              90                                                                      28.1   Jan-Mar   Mar-May   May-Dec

Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; BIC, bictegravir; C, cobicistat; DOR, doravirine; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; EVG, elvitegravir; FTC, emtricitabine; R, ritonavir; RAL, raltegravir; RPV, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

Standard 2019 Part D benefit: (1) \$415 deductible; (2) coverage phase: patients pay a percentage of drug's full list price (coinsurance), and the insurance plan pays the remainder; (3) coverage gap: starts at \$3820 in total drug cost, brand-name drug cost is shared between the patient (25%), manufacturer (70%), and insurance plan (5%), and generic drug cost (lamivudine and abacavir-lamivudine) is shared between the patient (37%) and insurance plan (63%); and (4) catastrophic coverage: starts at \$5100 in out-of-pocket costs (including manufacturer contribution during the gap), with costs shared by the patient (5%), insurance plan (15%), and Medicare (80%) for the rest of the year.

Patients may start the month in one phase, but end the month in a different phase.

Out-of-pocket costs in the gap phase equals 25% of drug price and in the catastrophic phase equals 5% of drug price. As such, SDs are not presented.

For regimens allowing either TAF and FTC or TDF and FTC, data are presented for TAF and FTC.

Under a standard 2019 Part D plan for 1 year of ART (price range, \$24 010-\$46 770; median, \$35 780), patients without subsidies were projected to contribute 9% to 14% (\$3270-\$4350), insurance plans 18% to 24% (\$5340-\$8450), manufacturers 6% to 11% (\$2370-\$2750), and Medicare 53% to 67% (\$12 770-\$31 270) ([Table 2](#zoi200134t2){ref-type="table"}). For 1 year of PrEP (price of both regimens ranges from \$20 560 to \$20 570), patients would contribute 15% (\$2990), insurance plans 22% (\$4570), manufacturers 13% (\$2750), and Medicare 50% (\$10 260). For a median-priced ART or PrEP regimen, monthly out-of-pocket costs would vary widely throughout the year as patients passed through each Part D phase ([Figure](#zoi200134f1){ref-type="fig"}). For patients with full LIS subsidies, Medicare would pay 67% to 76% of ART costs and 65% of PrEP costs.

###### Distribution of Antiretroviral Therapy and Preexposure Prophylaxis Cost for 1 Year Under a Standard 2019 Medicare Part D Plan

  Drug regimen              Annual Price, \$   Annual price, \$ (%)[^a^](#zoi200134t2n1){ref-type="table-fn"}                           
  ------------------------- ------------------ ---------------------------------------------------------------- ----------- ----------- -------------
  Antiretroviral therapy                                                                                                                
  BIC, TAF, and FTC         37 080             3860 (10)                                                        7000 (19)   2710 (7)    23 510 (63)
  DTG, ABC, and 3TC         35 430             3780 (11)                                                        6760 (19)   2710 (8)    22 190 (63)
  DTG+TAF and FTC           41 900             4060 (10)                                                        7770 (19)   2750 (7)    27 320 (65)
  RAL+TAF and FTC           38 890             3900 (10)                                                        7320 (19)   2750 (7)    24 910 (64)
  EVG, C, TDF, and FTC      37 900             3900 (10)                                                        7120 (19)   2710 (7)    24 170 (64)
  EVG, C, TAF, and FTC      36 130             3770 (10)                                                        6910 (19)   2750 (8)    22 700 (63)
  RAL+ABC and 3TC           25 420             3490 (14)                                                        6040 (24)   2370 (9)    13 520 (53)
  DRV, C, TAF, and FTC      46 770             4350 (9)                                                         8450 (18)   2710 (6)    31 270 (67)
  DRV, R+TAF, and FTC       44 230             4200 (9)                                                         8090 (18)   2730 (6)    29 210 (66)
  ATV, C+TAF, and FTC       40 250             4000 (10)                                                        7500 (19)   2730 (7)    26 030 (65)
  DRV, R+ABC, an d3TC       30 760             3760 (12)                                                        6640 (22)   2460 (8)    17 900 (58)
  DOR, TDF, an d3TC         26 390             3330 (13)                                                        5400 (20)   2710 (10)   14 960 (57)
  EFV, TDF, and FTC         33 420             3630 (11)                                                        6500 (19)   2750 (8)    20 540 (61)
  RPV, TAF, and FTC         32 880             3610 (11)                                                        6420 (20)   2750 (8)    20 110 (61)
  RPV, TDF, and FTC         32 860             3650 (11)                                                        6370 (19)   2710 (8)    20 140 (61)
  DTG+3TC                   24 010             3270 (14)                                                        5340 (22)   2630 (11)   12 770 (53)
  DRV and R+RAL             42 000             4080 (10)                                                        7760 (18)   2730 (7)    27 420 (65)
  DRV and R+3TC             26 330             3410 (13)                                                        5620 (21)   2610 (10)   14 690 (56)
  Median price              35 780             3770 (11)                                                        6830 (19)   2710 (8)    22 450 (63)
  Preexposure prophylaxis                                                                                                               
  TDF and FTC               20 570             2990 (15)                                                        4570 (22)   2750 (13)   10 260 (50)
  TAF and FTC               20 560             2990 (15)                                                        4570 (22)   2750 (13)   10 250 (50)

Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; BIC, bictegravir; C, cobicistat; DOR, doravirine; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; EVG, elvitegravir; FTC, emtricitabine; R, ritonavir; RAL, raltegravir; RPV, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

Cost paid by patient, insurance plan, manufacturer, and Medicare may not sum up exactly to price owing to rounding to nearest \$10. Percentages do not sum to 100% owing to rounding.

![Part D Cost-Sharing Between Patients, Insurance Plans, Manufacturers, and Medicare for Median-Priced Antiretroviral Therapy (ART) and Preexposure Prophylaxis (PrEP)](jamanetwopen-3-e202739-g001){#zoi200134f1}

Discussion {#H1-4-ZOI200134}
==========

In this national analysis, despite Medicare's mandate that Part D insurance plans cover ART and PrEP, high drug prices mean that patients face out-of-pockets costs of \$3000 to \$4000 annually under a standard benefit. Such cost-sharing indicates that for beneficiaries, affordable access to ART or PrEP may depend on them receiving taxpayer subsidies to lower out-of-pocket costs. In addition to highlighting the cost burden to patients, we found that most of the remaining ART and PrEP costs in Part D are borne by Medicare and taxpayers, rather than insurance plans or manufacturers.

For Medicare beneficiaries with HIV, high out-of-pocket cost may be associated with decreased treatment adherence and with both individual- and population-level harm. Other studies have shown that out-of-pocket cost can have a negative association with the use of ART and PrEP.^[@zoi200134r6],[@zoi200134r10],[@zoi200134r11]^ To the extent that affordability is associated with adherence, these results have important clinical and policy implications; the federal Ending the HIV Epidemic initiative will be successful only if patients have reliable access to HIV treatment and prevention. Patients' high out-of-pocket costs are associated with the large expense of ART and PrEP and how Part D designs cost-sharing for patients. In 2019, nearly all Part D insurance plans structured patient cost-sharing for ART and PrEP as a percentage of drug price rather than a fixed-dollar copayment. Such coinsurance is also applied during the coverage gap and catastrophic phases. Thus, patients pay a percentage of ARV prices during all Part D phases, and higher ARV prices will lead to greater out-of-pocket costs.^[@zoi200134r16]^ In addition, Part D varies cost-sharing in each coverage phase---deductible (100% coinsurance), coverage phase (median coinsurance of 29% for ART and 28% for PrEP), coverage gap phase (25%), and catastrophic phase (5%).^[@zoi200134r16]^ This variation causes sizable month-to-month fluctuation in patients' out-of-pocket costs. Beneficiaries have high copayments (≥\$500) during the first few months of each year and still face monthly copayments of \$100 to \$195 even during catastrophic coverage. Consideration should be given to redesigning Part D to focus on patients' out-of-pocket costs in predictable and stable dollar terms rather than as a changing percentage of drug price; this new design should also include a ceiling for patient out-of-pocket expenses.

Out-of-pocket costs for ARV will become even more important as more HIV beneficiaries age into Medicare, rather than qualifying based on disability, which often brings support through LIS. In 2014, of the Medicare beneficiaries 65 years or older with HIV, two-thirds initially qualified for Medicare based on age.^[@zoi200134r15]^ Nearly half of people with HIV are 50 years or older, and Medicare will be a critical source of coverage for this population in the decade ahead.^[@zoi200134r15],[@zoi200134r23],^ With the aging HIV population comes the need for PrEP access for older patients. In 2018, approximately 17% of new HIV infections in the United States occurred in persons 50 years or older,^[@zoi200134r3]^ and in 2016, 7% of individuals using PrEP were 55 years or older.^[@zoi200134r24]^ Over time, these individuals with indications for PrEP will increasingly enter Medicare owing to their age, without necessarily qualifying for LIS.

For beneficiaries with HIV who qualify for LIS, out-of-pocket costs are lower. Beneficiaries with dual eligibility with Medicaid or who have low income and assets qualify for full LIS, and cost-sharing is limited to a few dollars for drugs.^[@zoi200134r22]^ However, beneficiaries with only partial LIS due to higher income (between 135% and 150% of the federal poverty level) are required to pay 15% of drug costs. These individuals may still receive low-income subsidies from other federally or state-funded programs, such as the Ryan White AIDS Drug Assistance Program, which further subsidizes out-of-pocket costs for HIV care not covered by other insurance.^[@zoi200134r25]^ In either case, the cost burden of ART and PrEP shifts further to the taxpayer. For patients with full LIS, Medicare contributes up to three-fourths of annual ARV cost under a 2019 standard Part D benefit. Even for patients without LIS, Medicare pays half to two-thirds of ARV cost because high prices push patients quickly into catastrophic coverage, in which Medicare assumes 80% of the cost burden. Federal law prohibits Medicare from negotiating directly with manufacturers for lower drug prices.^[@zoi200134r21]^ Furthermore, both patient and Medicare contributions are calculated based on a drug's full list price without reflecting the rebates that insurance plans receive from manufacturers or pharmacy benefit managers.^[@zoi200134r21],[@zoi200134r26],[@zoi200134r27],[@zoi200134r28]^ Thus, as drug prices continue to increase, the cost assumed by patients and Medicare (taxpayers) will increase correspondingly. In 2017, Part D expenditures for ARVs exceeded \$4 billion,^[@zoi200134r14]^ which could increase substantially as efforts to expand the use of ART and PrEP proceed.

As currently designed, Part D insurance plans would cover less than one-fourth of the cost of ART and PrEP. These calculations exclude rebates and discounts from manufacturers and pharmacy benefit managers. Insurance plans' actual contributions are likely lower, although their exact magnitude remains unknown because rebate information is proprietary. For manufacturers, their 70% price discount during the coverage gap represented only a modest contribution (≤\$2750) and was frequently 10% or less of ARV prices.

Proposed legislation would redesign Part D to lower patients' cost-sharing by capping annual out-of-pocket costs or passing discounts and rebates directly to patients.^[@zoi200134r16],[@zoi200134r21],[@zoi200134r26],[@zoi200134r27],[@zoi200134r28]^ Others advocate shifting a greater proportion of cost away from Medicare during the catastrophic coverage phase and onto insurance plans (50%) and manufacturers (30%).^[@zoi200134r26],[@zoi200134r27]^ However, there is concern that doing so may increase premiums and may increase drug prices further. Thus, we believe that there is a need to address ART and PrEP price directly, such as allowing Medicare to negotiate drug prices, imposing penalties if drug prices increase beyond the general inflation rate,^[@zoi200134r13],[@zoi200134r16]^ setting US prices based on lower prices in other countries, and recouping government-funded research support in the case of PrEP development.^[@zoi200134r29]^ Our findings suggest that current ART and PrEP costs fall largely on patients and taxpayers, which is not conducive to the success of the Ending the HIV Epidemic initiative. It seems to be apparent that achieving a 90% incidence reduction in HIV by 2030 will require legislation to manage the price of these drugs.

Limitations {#H2-1-ZOI200134}
-----------

This study has some limitations. We projected annual cost-sharing based only on use of each ART or PrEP and no other drugs under a standard 2019 Part D insurance plan. Actual out-of-pocket cost would depend on insurance plan--specific benefit parameters (eg, deductibles and terms for cost-sharing) as well as the cost of beneficiaries' other prescriptions.

Conclusions {#H1-5-ZOI200134}
===========

The high prices of ART and PrEP and the design of Medicare Part D mean that patients can face thousands of dollars in out-of-pocket cost for drugs for HIV treatment and prevention. Thus, many beneficiaries with Part D may struggle to afford access to ART and PrEP unless they receive taxpayer-funded subsidies. Furthermore, Medicare (taxpayers), rather than health insurance plans or manufacturers, appears to shoulder much of the remaining cost burden. We believe that to realize Ending the HIV Epidemic initiative goals, reforms must quickly and effectively address the high price of ARVs as well as redesign Part D cost-sharing.
